GT Biopharma (NASDAQ:GTBP – Get Free Report) will likely be posting its Q3 2026 results before the market opens on Friday, November 13th. Analysts expect GT Biopharma to announce earnings of ($2.50) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 20, 2026 at 9:30 AM ET.
GT Biopharma (NASDAQ:GTBP – Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.04).
GT Biopharma Stock Performance
Shares of NASDAQ:GTBP opened at $3.96 on Wednesday. GT Biopharma has a 52-week low of $3.88 and a 52-week high of $28.75. The business has a 50-day moving average price of $6.37 and a 200-day moving average price of $9.36.
Wall Street Analyst Weigh In
GTBP has been the subject of a number of recent research reports. Wall Street Zen lowered shares of GT Biopharma to a “strong sell” rating in a research report on Saturday, September 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GT Biopharma in a research report on Friday, October 2nd. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat.com, GT Biopharma currently has an average rating of “Sell”.
Get Our Latest Analysis on GTBP
GT Biopharma Company Profile
GT Biopharma, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research centers on natural killer (NK) cells, a component of the immune system that can recognize and destroy abnormal cells. GT Biopharma’s principal technology is its TriKE (trispecific killer engager) platform. These engineered molecules are designed to bind a cancer-associated target, activate NK cells through the CD16 receptor, and enhance NK-cell activity through an interleukin-15 component.
Read More
- Five stocks we like better than GT Biopharma
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for GT Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GT Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
